Corcept Therapeutics vs Telix Pharmaceuticals
Telix Pharmaceuticals reported revenue of $804 million in fiscal 2025, about the same as Corcept Therapeutics' $761 million in fiscal 2025. Corcept Therapeutics' revenue grew 12.8% in its latest year, and Telix Pharmaceuticals' grew 55.6%. Corcept Therapeutics had an operating margin of 5.9%, against 3.7% at Telix Pharmaceuticals. Free cash flow was $142 million at Corcept Therapeutics and −$43 million at Telix Pharmaceuticals.
Side by side
| Corcept Therapeutics | Telix Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $761M | $804M |
| Revenue growth | 12.8% | 55.6% |
| Revenue growth a year, last 5 years | 16.6% | — |
| Gross margin | 98.3% | 53.0% |
| Operating margin | 5.9% | 3.7% |
| Net margin | 13.1% | −0.9% |
| Free cash flow | $142M | −$43M |
| Free cash flow margin | 18.6% | −5.3% |
| Return on capital | 15.7% | 5.0% |
| Net debt to EBITDA | −8.1x | 5.1x |
| Dividends and buybacks | $173M | $0M |
| Change in diluted share count | 5.7% | −2.1% |
| Last close | $64.98 | $8.71 |
| P/E at the last close | 51.2× | — |
| Insider trades, last 12 months | bought $3.3 million, sold $93.4 million | bought $1.0 million, sold $0 |
| Piotroski F-score | 3 of 9 | 2 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Corcept TherapeuticsTelix Pharmaceuticals
Operating margin
Percent of revenue
Corcept TherapeuticsTelix Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Corcept TherapeuticsTelix Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Corcept Therapeutics and Telix Pharmaceuticals pages.